<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1038</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTERIAL HYPERTENSION</subject></subj-group></article-categories><title-group><article-title>Комбинация дигидропиридиновых и недигидропиридиновых антагонистов кальция в лечении больных артериальной гипертонией и сопутствующей ишемической болезнью сердца: эффективность и безопасность</article-title><trans-title-group xml:lang="en"><trans-title>Combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients with arterial hypertension and coronary heart disease: efficacy and safety</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Искендеров</surname><given-names>Б. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Iskanderov</surname><given-names>B. G.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">giuv@sura.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лохина</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lokhina</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">giuv@sura.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурмистрова</surname><given-names>Л. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Burmistrova</surname><given-names>L. F.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">giuv@sura.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казанцева</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazantseva</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">giuv@sura.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богданова</surname><given-names>С. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogdanova</surname><given-names>S. R.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">giuv@sura.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пензенский институт усовершенствования врачей, Пенза</institution></aff><aff xml:lang="en"><institution>Penza Institute for Continuous Medical Education, Penza</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2005</year></pub-date><volume>4</volume><issue>6, ч.II</issue><fpage>38</fpage><lpage>43</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Искендеров Б.Г., Лохина Т.В., Бурмистрова Л.Ф., Казанцева Л.В., Богданова С.Р., 2005</copyright-statement><copyright-year>2005</copyright-year><copyright-holder xml:lang="ru">Искендеров Б.Г., Лохина Т.В., Бурмистрова Л.Ф., Казанцева Л.В., Богданова С.Р.</copyright-holder><copyright-holder xml:lang="en">Iskanderov B.G., Lokhina T.V., Burmistrova L.F., Kazantseva L.V., Bogdanova S.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1038">https://cardiovascular.elpub.ru/jour/article/view/1038</self-uri><abstract><p>Цель. Изучить антигипертензивное и антиишемическое влияния на структурно-функциональное состояние сердца, оценить безопасность комбинированной терапии антагонистами кальция (АК) дигидропиридинового и недигидропиридинового ряда. Материал и методы. Обследован 31 больной артериальной гипертонией II-III стадии, II степени (ВНОК, 2001) и сопутствующей ишемической болезнью сердца с приступами стенокардии напряжения II-III функциональных классов. Использовали результаты суточного мониторирования артериального давления (АД) и электрокардиограммы, допплер-эхокардиографии. Проводилась комбинированная терапия амлодипином и верапамилом ретард в течение 24 недель. Результаты. На фоне терапии у 77,4% больных наблюдали полный антигипертензивный эффект (АД&lt;140/90 мм рт.ст.) и у 22,6% – частичный (снижение диастолического АД на 10 мм рт.ст.). Индекс массы миокарда левого желудочка уменьшился в среднем на 24,9±2,3 г/м2 (p&lt;0,01) и улучшилась диастолическая функция: соотношение скорости потока в фазу раннего и позднего наполнения увеличилось на 10,3% (p&lt;0,05); время изоволюмического расслабления уменьшилось на 13,6% (p&lt;0,01); сократилась глубина максимальной депрессии сегмента ST с 2,3±0,2 до 1,5±0,1 мм, продолжительность и частота безболевой ишемии миокарда. Частота побочных действий препаратов по сравнению с монотерапией была в 1,5-4 раза меньше. Заключение. Комбинация дигидропиридиновых и недигидропиридиновых АК обладает достаточно высоким антигипертензивным и антиишемическим действиями, а также кардиопротективным действием и хорошей переносимостью.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study antihypertensive and anti-ischemic effects on structural and functional heart status, and assess treatment safety for combination of dihydropyridine and non-dihydropyridine calcium antagonists (CA). Material and methods. The authors examined 31 patients with Stage II-III, level II arterial hypertension (AH) (Society of Cardiology of the Russian Federation, 2001), and coronary heart disease (CHD), effort angina, Functional Class (FC) II-III. Twenty-four-hour electrocardiography (ECG) and blood pressure (BP) monitoring, Doppler echocardiography (EchoCG) were performed. Combined therapy with amlodipine and verapamil retard lasted for 24 weeks. Results. During the treatment, in 77.4% of the patients, complete antihypertensive effect (BP&lt;140/90 mm Hg) was observed; in 22.6%, this effect was partial (diastolic BP decrease by 10 mm Hg). Mean decrease in left ventricular myocardial mass index was 24.9±2.3 g/m2 (p&lt;0.01). Diastolic function improved: early and late flow velocity ratio (E/A) increased by 10.3% (p&lt;0.05); isovolumic relaxation time reduced by 13.6% (p&lt;0.01). Maximal depth of ST segment depression decreased from 2.3±0.2 to 1.5±0.1 mm. Duration and frequency of painless myocardial ischemia decreased, too. Adverse effect rate was by 1.5-4 times lower than for monotherapy. Conclusion. Combination of dihydropyridine and non-dihydropyridine CA demonstrated its antihypertensive, anti-ischemic, and cardioprotective effects, and was well tolerated.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>антагонисты кальция</kwd><kwd>верапамил ретард</kwd><kwd>амлодипин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>calcium antagonists</kwd><kwd>verapamil retard</kwd><kwd>amlodipin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">2003 European Society of Hypertension – European Society of Cardiology Guidelines for the management of arterial Hypertension. Guidelines Committee. J Hypertens 2003; 21: 1011-53.</mixed-citation><mixed-citation xml:lang="en">2003 European Society of Hypertension – European Society of Cardiology Guidelines for the management of arterial Hypertension. Guidelines Committee. J Hypertens 2003; 21: 1011-53.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Abernethy DR, Schwartz JB. Drug therapy: Calcium-Antagonists Drugs. N Engl J Med 1999; 34: 1447-57.</mixed-citation><mixed-citation xml:lang="en">Abernethy DR, Schwartz JB. Drug therapy: Calcium-Antagonists Drugs. N Engl J Med 1999; 34: 1447-57.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Небиеридзе Д.В. Антагонисты кальция в практике кардиолога – один класс, разные свойства. Cons med 2004; 5(Прилож): 3-6.</mixed-citation><mixed-citation xml:lang="en">Небиеридзе Д.В. Антагонисты кальция в практике кардиолога – один класс, разные свойства. Cons med 2004; 5(Прилож): 3-6.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lefrandi JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001; 14: 1083-9.</mixed-citation><mixed-citation xml:lang="en">Lefrandi JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001; 14: 1083-9.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Бойцов С.А., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией. Метод письмо. Москва 2004; 47с.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Бойцов С.А., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией. Метод письмо. Москва 2004; 47с.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">The ALLHAT Officers and Coordinations. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker is diuretic (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation><mixed-citation xml:lang="en">The ALLHAT Officers and Coordinations. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker is diuretic (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pepine CJ, Handberg-Thurmond E. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST) JACC 1998; 32: 1228-37.</mixed-citation><mixed-citation xml:lang="en">Pepine CJ, Handberg-Thurmond E. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST) JACC 1998; 32: 1228-37.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rebnqvist N, Neimdabl A, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angine pectoris. The angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76- 81.</mixed-citation><mixed-citation xml:lang="en">Rebnqvist N, Neimdabl A, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angine pectoris. The angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76- 81.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Opie L, Schall R. Evidence-based evaluations of calcium channel blockers for hypertension. JACC 2002; 39: 315-22.</mixed-citation><mixed-citation xml:lang="en">Opie L, Schall R. Evidence-based evaluations of calcium channel blockers for hypertension. JACC 2002; 39: 315-22.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Staessen J, Ji-Guang Wang, Thijs L. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trail. Am J Hypertens 2002; 15: 85S-93.</mixed-citation><mixed-citation xml:lang="en">Staessen J, Ji-Guang Wang, Thijs L. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trail. Am J Hypertens 2002; 15: 85S-93.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г.П. Недигидропиридиновые антагонисты кальция в терапии больных ишемической болезнью сердца и артериальной гипертонией. Кардиоваск тер профилак 2004; 2: 31- 6.</mixed-citation><mixed-citation xml:lang="en">Арутюнов Г.П. Недигидропиридиновые антагонисты кальция в терапии больных ишемической болезнью сердца и артериальной гипертонией. Кардиоваск тер профилак 2004; 2: 31- 6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев В.С., Кобалава Ж.Д. Комбинированная фармакотерапия артериальной гипертонии. Сердце 2002; 5: 228-31.</mixed-citation><mixed-citation xml:lang="en">Моисеев В.С., Кобалава Ж.Д. Комбинированная фармакотерапия артериальной гипертонии. Сердце 2002; 5: 228-31.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Devereux R, Reichek N. Echocardiographic assessment of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-8.</mixed-citation><mixed-citation xml:lang="en">Devereux R, Reichek N. Echocardiographic assessment of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zanchetti A, Rosei EA, Palu CD, et al. The Verapamil in Hypertension and Atherosclerosis Study (VASH): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.</mixed-citation><mixed-citation xml:lang="en">Zanchetti A, Rosei EA, Palu CD, et al. The Verapamil in Hypertension and Atherosclerosis Study (VASH): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
